“The higher the better” seems to be no longer true for HDL-cholesterol

Authors: Hana Rosolová
Authors‘ workplace: Centrum preventivní kardiologie II. interní kliniky LF UK a FN Plzeň
Published in: Vnitř Lék 2018; 64(12): 1153-1155


It is very well known from the old epidemiological population studies, that HDL-cholesterol (HDL-C) was in a negative association with coronary events risk. New studies have occurred during the last 10 years that the mentioned association has in fact the U-shaped curve, i.e. lower and higher levels of HDL-C then the optimal one are in an exponential increasing risk. The association of high HDL-C levels with cardiovascular risk is not explained clearly. There might be a hypothesis concerning a change of function of large HDL particles riched of cholesterol esters, which become to be cholesterol donors for the arteries.

Key words:

cardiovascular risk – HDL-cholesterol – HDL particles

  1. Multiple Risk Factor Intervention Trial Research Group: MRFIT: a National study of primary prevention of coronary heart disease. JAMA 1976; 235(8): 825–827.
  2. Allard-Ratick M, Fonarow G. HDL-cholesterol is associated with adverse cardiovascular outcomes. European Society of Cardiology meeting, Munich, Germany, Aug. 25, 2018. Dostupné z WWW: <https://content.zone-secure.net/escardio_congress_2018/#page=1>.
  3. Van der Steeg WA, Holme I, Boekholdt SM et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies J Am Coll Cardiol 2008; 51(6): 634–642. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2007.09.060>.
  4. Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J 2017; 38(32): 2478–2486. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehx163>.
  5. Kastelein JJ, van Leuven SI, Burgess L et al. Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia. N Engl J Med 2007; 356(16): 1620–1630. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa071359>.
  6. Cannon CP, Shah S, Dansky HM et al. Safety of anacetrapib in patients with orat high risk for coronary heart disease. N Engl J Med 2010; 363(25): 2406–2415. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1009744>.
  7. Bowman L, Hopewell JC, Chen F et al. [HPS3/TIMI55-REVEAL Collaborative Group]. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med 2017; 377(13): 1217–1227. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1706444>.
  8. Tall AR, Costet P, Wang N. Regulation and mechanisms of macrophage cholesterol efflux. J Clin Invest 2002; 110(7): 899–904. Dostupné z DOI: <http://dx.doi.org/10.1172/JCI16391>.
  9. Navab M, Anatharamaiah GM, Reddy ST et al. Mechanisms of disease: proatherogenic HDL – anevolving field. Nat Clin Pract Endocrinol Metab 2006; 2(9): 504–511. Dostupné z DOI: <http://dx.doi.org/10.1038/ncpendmet0245>.
Diabetology Endocrinology Internal medicine
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account